Stargardt disease: Clinical features, molecular genetics, animal models and therapeutic options

British Journal of Ophthalmology

Volumn 101, Issue 1, 2017, Pages 25-30

  Tanna, Preena ^a,b   Strauss, Rupert W ^a,b,c   Fujinami, Kaoru ^a,b,d   Michaelides, Michel ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Dystrophy; Imaging; Retina

Indexed keywords

ADAPTIVE OPTICS SCANNING LIGHT OPHTHALMOSCOPY; AUTOFLUORESCENCE; CLINICAL FEATURE; DISEASE COURSE; FUNDUS AUTOFLUORESCENCE; GENE REPLACEMENT THERAPY; HUMAN; MOLECULAR GENETICS; OPHTHALMOSCOPY; PATHOGENESIS; REVIEW; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; STARGARDT DISEASE; ANIMAL; DISEASE MODEL; ELECTRORETINOGRAPHY; FEMALE; GENE THERAPY; GENETICS; GENOTYPE; MACULAR DEGENERATION; MOLECULAR BIOLOGY; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES;

ABC TRANSPORTER; ABCA4 PROTEIN, HUMAN;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; FEMALE; GENETIC THERAPY; GENOTYPE; HUMANS; MACULAR DEGENERATION; MOLECULAR BIOLOGY; MUTATION; PHENOTYPE;

EID: 84982793861     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2016-308823     Document Type: Review

References (79)

1. Michaelides M, Hunt DM, Moore AT. The genetics of inherited macular dystrophies. J Med Genet 2003;40:641-50.
2. Fujinami K, Lois N, Davidson AE, et al. A longitudinal study of stargardt disease: clinical and electrophysiologic assessment, progression, and genotype correlations. Am J Ophthalmol 2013;155:1075-88.
3. Fujinami K, Zernant J, Chana RK, eta/. Clinical and molecular characteristics of childhood-onset Stargardt disease. Ophthalmology 2015;122:326-34.
4. Molday RS. Insights into the molecular properties of ABCA4 and its role in the visual cycle and stargardt disease. Prog Mo/Biol Trans/Sci 2015;134:415-31.
5. Strauss RW, Ho A, Munoz B, et al. The natural history of the progression of atrophy secondary to Stargardt disease (ProgStar) studies: design and baseline characteristics: ProgStar Report No. 1. Ophthalmology 2016;123:817-28.
6. Burke TR, Tsang SH. Allelic and phenotypic heterogeneity in ABCA4 mutations. Ophthalmic Genet 2011;32:165-74.
7. Lambertus S, van Huet RA, Bax NM, et al. Early-onset stargardt disease: phenotypic and genotypic characteristics. Ophthalmology 2015;122:335-44.
8. Allikmets R, Singh N, Sun H, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 1997;15:236-46.
9. Fujinami K, Zernant J, Chana RK, et al. ABCA4 gene screening by next-generation sequencing in a British cohort. Invest Ophthalmol Vis Sci 2013;54:6662-74.
10. Zernant J, Schubert C, Im KM, et al. Analysis of the ABCA4 gene by next-generation sequencing. Invest Ophthalmol Vis Sci 2011;52:8479-87.
11. Haji Abdollahi S, Hirose T. Stargardt-Fundus flavimaculatus: recent advancements and treatment. Semin Ophthalmol 2013;28:372-6.
12. Michaelides M, Chen LL, Brantley MA Jr, et al. ABCA4 mutations and discordant ABCA4 alleles in patients and siblings with bull's-eye maculopathy. Br J Ophthalmol 2007;91:1650-5.
13. Fujinami K, Lois N, Mukherjee R, et al. A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. Invest Ophthalmol Vis Sci 2013;54:8181-90.
14. Fujinami K, Sergouniotis PI, Davidson AE, et al. The clinical effect of homozygous ABCA4 alleles in 18 patients. Ophthalmology 2013;120:2324-31.
15. Fujinami K, Sergouniotis PI, Davidson AE, et al. Clinical and molecular analysis of Stargardt disease with preserved foveal structure and function. Am J Ophthalmol 2013;156:487-501 e1.
16. Westeneng-van Haaften SC, Boon CJ, Cremers FP, et al. Clinical and genetic characteristics of late-onset Stargardt's disease. Ophthalmology 2012;119: 1199-210.
17. Lois N, Holder GE, Bunce C, et al. Phenotypic subtypes of Stargardt macular dystrophy-fundus flavimaculatus. Arch Ophthalmol 2001;119:359-69.
18. Fishman GA, Stone EM, Grover S, et al. Variation of clinical expression in patients with Stargardt dystrophy and sequence variations in the ABCR gene. Arch Ophthalmol 1999;117:504-10.
19. Rotenstreich Y, Fishman GA, Anderson RJ. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology 2003;110:1151-8.
20. Burke TR, Tsang SH, Zernant J, et al. Familial discordance in Stargardt disease. Mo Vis 2012;18:227-33.
21. Singh R, Fujinami K, Chen LL, et al. Longitudinal follow-up of siblings with a discordant Stargardt disease phenotype. Acta Ophthalmol 2014;92:e331-2.
22. Smith J, Ward D, Michaelides M, et al. New and emerging technologies for the treatment of inherited retinal diseases: a horizon scanning review. Eye (Lond) 2015;29:1131-40.
23. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 2015;385:509-16.
24. Dalkara D, Goureau O, Marazova K, et al. Let there be light: gene and cell therapy for blindness. Hum Gene Ther 2016;27:134-47.
25. Saad L, Washington I. Can vitamin A be improved to prevent blindness due to age-related macular degeneration, Stargardt disease and other retinal dystrophies? Adv Exp Med Biol 2016;854:355-61.
26. Zernant J, Xie YA, Ayuso C, et al. Analysis of the ABCA4 genomic locus in Stargardt disease. Hum Mol Genet 2014;23:6797-806.
27. van Huet RA, Bax NM, Westeneng-Van Haaften SC, et al. Foveal sparing in Stargardt disease. Invest Ophthalmol Vis Sci 2014;55:7467-78.
28. Strauss RW, Munoz B, Wolfson Y, et al. Assessment of estimated retinal atrophy progression in Stargardt macular dystrophy using spectral-domain optical coherence tomography. Br J Ophthalmol 2015;100:956-62.
29. Gomes NL, Greenstein VC, Carlson JN, et al. A comparison of fundus autofluorescence and retinal structure in patients with Stargardt disease. Invest Ophthalmol Vis Sci 2009;50:3953-9.
30. Fujinami K, Singh R, Carroll J, et al. Fine central macular dots associated with childhood-onset Stargardt disease. Acta Ophthalmol 2014;92:e157-9.
31. Lee W, Noupuu K, Oll M, et al. The external limiting membrane in early-onset Stargardt disease. Invest Ophthalmol Vis Sci 2014;55:6139-49.
32. Fujinami K, Akahori M, Fukui M, et al. Stargardt disease with preserved central vision: identification of a putative novel mutation in ATP-binding cassette transporter gene. Acta Ophthalmol 2011;89:e297-8.
33. Song H, Rossi EA, Latchney L, et al. Cone and rod loss in Stargardt disease revealed by adaptive optics scanning light ophthalmoscopy. JAMA Ophthalmol 2015;133:1198-203.
34. Aleman TS, Cideciyan AV, Windsor EA, et al. Macular pigment and lutein supplementation in ABCA4-associated retinal degenerations. Invest Ophthalmol Vis Sci 2007;48:1319-29.
35. von Ruckmann A, Fitzke FW, Bird AC. Distribution of fundus autofluorescence with a scanning laser ophthalmoscope. Br J Ophthalmol 1995;79:407-12.
36. Delori FC, Dorey CK, Staurenghi G, et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995;36:718-29.
37. Wabbels B, Demmler A, Paunescu K, et al. Fundus autofluorescence in children and teenagers with hereditary retinal diseases. Graefes Arch Clin Exp Ophthalmol 2006;244:36-45.
38. Boon CJ, Jeroen Klevering B, Keunen JE, et al. Fundus autofluorescence imaging of retinal dystrophies. Vision Res 2008;48:2569-77.
39. Lois N, Halfyard AS, Bird AC, et al. Fundus autofluorescence in Stargardt macular dystrophy-fundus flavimaculatus. Am J Ophthalmol 2004;138:55-63.
40. Smith RT, Gomes NL, Barile G, et al. Lipofuscin and autofluorescence metrics in progressive STGD. Invest Ophthalmol Vis Sci 2009;50:3907-14.
41. McBain VA, Townend J, Lois N. Progression of retinal pigment epithelial atrophy in stargardt disease. Am J Ophthalmol 2012;154:146-54.
42. Burke TR, Duncker T, Woods RL, et al. Quantitative fundus autofluorescence in recessive Stargardt disease. Invest Ophthalmol Vis Sci 2014;55:2841-52.
43. Sparrow JR, Gregory-Roberts E, Yamamoto K, et al. The bisretinoids of retinal pigment epithelium. Prog Retin Eye Res 2012;31:121-35.
44. Cideciyan AV, Swider M, Aleman TS, et al. Reduced-illuminance autofluorescence imaging in ABCA4-associated retinal degenerations. J Opt Soc Am A Opt Image Sci Vis 2007;24:1457-67.
45. Strauss RW, Munoz B, Jha A, et al. Comparison of short-wavelength reduced-illuminance and conventional autofluorescence imaging in Stargardt Macular Dystrophy. Am J Ophthalmol 2016;168:269-78.
46. Burke TR, Yzer S, Zernant J, et al. Abnormality in the external limiting membrane in early Stargardt disease. Ophthalmic Genet 2013;34:75-7.
47. Chen Y, Ratnam K, Sundquist SM, et al. Cone photoreceptor abnormalities correlate with vision loss in patients with Stargardt disease. Invest Ophthalmol Vis Sci 2011;52:3281-92.
48. Scoles D, Sulai YN, Langlo CS, et al. In vivo imaging of human cone photoreceptor inner segments. Invest Ophthalmol Vis Sci 2014;55:4244-51.
49. Michaelides M, Zakka F, Aboshiha J, et al. High-resolution imaging in stargardt disease: preliminary observations in preparation for intervention [abstract]. Invest Ophthalmol Vis Sci 2014;55:5016.
50. Razeen MM, Cooper RF, Langlo CS, et al. Correlating photoreceptor mosaic structure to clinical findings in Stargardt disease. Transl Vis Sci Technol 2016;5:6.
51. Jaakson K, Zernant J, Kulm M, et al. Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum Mutat 2003;22:395-403.
52. Valverde D, Riveiro-Alvarez R, Bernal S, et al. Microarray-based mutation analysis of the ABCA4 gene in Spanish patients with Stargardt disease: evidence of a prevalent mutated allele. Mol Vis 2006;12:902-8.
53. Riveiro-Alvarez R, Lopez-Martinez MA, Zernant J, et al. Outcome of ABCA4 disease-associated alleles in autosomal recessive retinal dystrophies: retrospective analysis in 420 Spanish families. Ophthalmology 2013;120:2332-7.
54. Rosenberg T, Klie F, Garred P, et al. N965S is a common ABCA4 variant in Stargardt-related retinopathies in the Danish population. Mol Vis 2007;13:1962-9.
55. Wiszniewski W, Zaremba CM, Yatsenko AN, et al. ABCA4 mutations causing mislocalization are found frequently in patients with severe retinal dystrophies. Hum Mol Genet 2005;14:2769-78.
56. Briggs CE, Rucinski D, Rosenfeld PJ, et al. Mutations in ABCR (ABCA4) in patients with Stargardt macular degeneration or cone-rod degeneration. Invest Ophthalmol Vis Sci 2001;42:2229-36.
57. Burke TR, Fishman GA, Zernant J, et al. Retinal phenotypes in patients homozygous for the G1961E mutation in the ABCA4 gene. Invest Ophthalmol Vis Sci 2012;53:4458-67.
58. Yatsenko AN, Shroyer NF, Lewis RA, et al. Late-onset Stargardt disease is associated with missense mutations that map outside known functional regions of ABCR (ABCA4). Hum Genet 2001;108:346-55.
59. Cideciyan AV, Aleman TS, Swider M, et al. Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. Hum Mol Genet 2004;13:525-34.
60. Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv Exp Med Biol 2010;703:105-25.
61. Charbel Issa P, Barnard AR, Singh MS, et al. Fundus autofluorescence in the Abca4(-/-) mouse model of Stargardt disease-correlation with accumulation of A2E, retinal function, and histology. Invest Ophthalmol Vis Sci 2013;54:5602-12.
62. Shroyer NF, Lewis RA, Yatsenko AN, et al. Cosegregation and functional analysis of mutant ABCR (ABCA4) alleles in families that manifest both Stargardt disease and age-related macular degeneration. Hum Mol Genet 2001;10:2671-8.
63. Ernest PJ, Boon CJ, Klevering BJ, et al. Outcome of ABCA4 microarray screening in routine clinical practice. Mol Vis 2009;15:2841-7.
64. Klevering BJ, Yzer S, Rohrschneider K, et al. Microarray-based mutation analysis of the ABCA4 (ABCR) gene in autosomal recessive cone-rod dystrophy and retinitis pigmentosa. Eur J Hum Genet 2004;12:1024-32.
65. Travis GH, Golczak M, Moise AR, et al. Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. Annu Rev Pharmacol Toxicol 2007;47:469-512.
66. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005;80:595-606.
67. Sparrow JR, Fishkin N, Zhou J, et al. A2E, a byproduct of the visual cycle. Vision Res 2003;43:2983-90.
68. Weng J, Mata NL, Azarian SM, et al. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 1999;98:13-23.
69. Chen Y, Okano K, Maeda T, et al. Mechanism of all-trans-retinal toxicity with implications for stargardt disease and age-related macular degeneration. J Biol Chem 2012;287:5059-69.
70. Radu RA, Mata NL, Bagla A, et al. Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt's macular degeneration. Proc Natl Acad Sci USA 2004;101:5928-33.
71. Radu RA, Yuan Q, Hu J, et al. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation. Invest Ophthalmol Vis Sci 2008;49:3821-9.
72. Teussink MM, Lee MD, Smith RT, et al. The effect of light deprivation in patients with Stargardt disease. Am J Ophthalmol 2015;159:964-72 e2.
73. Warrington KH Jr, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006;119:571-603.
74. Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008;118:1955-64.
75. Han Z, Conley SM, Naash MI. Gene therapy for Stargardt disease associated with ABCA4 gene. Adv Exp Med Biol 2014;801:719-24.
76. Audo I, Weleber R, Stout T, et al. Early findings in a Phase I/IIa clinical program for Stargardt disease (STGD1, MIM #248200) [abstract]. Invest Ophthalmol Vis Sci 2015;56:3819.
77. Charbel Issa P, Barnard AR, Herrmann P, et al. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. Proc Natl AcadSciUSA 2015;112:8415-20.
78. Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem 2011;286:7958-65.
79. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open 2014;4:e004015.